Pioglitazone improves CV risk markers in type 2 diabetes

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1495, 2005-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone improves lipid profiles in type 2 diabetes

Inpharma, Vol. 1, Iss. 1243, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Spotlight on pioglitazone in type 2 diabetes

Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy

By Schöfl Christof

Clinical Drug Investigation, Vol. 25, Iss. 5, 2005-01 ,pp. : 341-345

Adis International

Access to resources Recommend Favorite

Pioglitazone pays dividends in type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1612, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Review of approved pioglitazone combinations for type 2 diabetes

By Forst Thomas Hanefeld Markolf Pfüützner Andreas

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1571-1584

Informa Healthcare

Access to resources Recommend Favorite